Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models

Neuroscience

Volumn 169, Issue 2, 2010, Pages 863-873

  Ghelardini, C ^a   Desaphy, J F ^b   Muraglia, M ^b   Corbo, F ^b   Matucci, R ^a   Dipalma, A ^b   Bertucci, C ^c   Pistolozzi, M ^c   Nesi, M ^a   Norcini, M ^a   Franchini, C ^b   Camerino, D Conte ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Analgesia; Chronic constriction injury; Chronic pain; Oxaliplatin associated pain; Sodium channel blocker; Use dependence

Indexed keywords

1 BENZYL N (2,6 DIMETHYLPHENYL) 3 PYRROLIDINE CARBOXAMIDE; ANALGESIC AGENT; NEP1; OXALIPLATIN; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.7; TOCAINIDE; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PATCH CLAMP; PRIORITY JOURNAL; RAT; SCIATIC NERVE;

ANALGESICS; ANIMALS; CELL LINE; CELL SURVIVAL; HUMANS; HYPERALGESIA; MALE; MUSCLE PROTEINS; PAIN; PATCH-CLAMP TECHNIQUES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TOCAINIDE;

EID: 77954621746     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.05.019     Document Type: Article

References (45)

1. + channel kinetics on rat sensory neurons. Eur J Pharmacol 2000, 406:25-32.
2. Akopian A.N., Souslova V., England S., Okuse K., Ogata N., Ure J., Smith A., Kerr B.J., McMahon S.B., Boyce S. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999, 2:541-548.
3. Barltrop J.A., Owen T.C., Cory A.H., Cory J.C. 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl) tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability indicators. Bioorg Med Chem Lett 1991, 1:611-614.
4. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
5. Benoit E., Brienza S., Dubois J.M. Oxalipaltin, an anticancer agent affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys 2006, 25:263-276.
6. Bertucci C., Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 2002, 9:1463-1481.
7. Browne L.E., Clare J.J., Wray D. Functional and pharmacological properties of human and rat Nav18 channels. Neuropharmacology 2009, 56:905-914.
8. Cavaletti G., Tredici G., Petruccioli M.G., Dondè E., Tredici P., Marmiroli P., Minoia C., Ronchi A., Bayssas M., Etienne G.G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001, 37:2457-2463.
9. Challapalli V., Tremont-Lukats I.W., McNicol E.D., Lau J., Carr D.B. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005, 19. CD003345.
10. Conte Camerino D., Tricarico D., Desaphy J.F. Ion channel pharmacology. Neurotherapeutics 2007, 4:184-198.
11. Cox J.J., Reimann F., Nicholas A.K. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444:894-898.
12. Cummins T.R., Sheets P.L., Waxman S.G. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 2007, 131:243-257.
13. Cummins T.R., Howe J.R., Waxman S.G. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 1998, 18:9607-9619.
14. De Luca A., Natuzzi F., Desaphy J.F., Loni G., Lentini G., Franchini C., Tortorella V., Conte Camerino D. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Mol Pharmacol 2000, 57:268-277.
15. De Luca A., Talon S., De Bellis M., Desaphy J.F., Lentini G., Corbo F., Scilimati A., Franchini C., Tortorella V., Conte Camerino D. Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol Pharmacol 2003, 64:932-945.
16. Desaphy J.F., Conte Camerino D., Franchini C., Lentini G., Tortorella V., De Luca A. Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a mode of myotonia induced by ATX. Br J Pharmacol 1999, 128:1165-1174.
17. Desaphy J.F., De Luca A., Didonna M.P., George A.L., Conte Camerino D. Different flecainide sensitivity of hNav14 channels and myotonic mutants explained by state-dependent block. J Physiol 2004, 554:321-334.
18. Desaphy J.F., De Luca A., Tortorella P., De Vito D., George A.L., Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 2001, 57:1849-1857.
19. Desaphy J.F., Dipalma A., De Bellis M., Costanza T., Gaudioso C., Delmas P., George A.L., Conte Camerino D. Involvement of voltage-gated sodium channels blockade in the analgesic action of orphenadrine. Pain 2009, 142:225-235.
20. Dib-Hajj S.D., Fjell J., Cummins T.R., Zheng Z., Fried K., LaMotte R., Black J.A., Waxman S.G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999, 83:591-600.
21. Dib-Hajj S.D., Binshtok A.M., Cummins T.R., Jarvis M.F., Samad T., Zimmermann K. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev 2009, 60:65-83.
22. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Kalso E.A., Loeser J.D., Miaskowski C., Nurmikko T.J., Portenoy R.K., Rice A.S., Stacey B.R., Treede R.D., Turk D.C., Fallace M.S. Pharmacologic management of neuropathic pain: evidence-based recommendation. Pain 2007, 132:237-251.
23. Finnerup N.B., Biering-Sorensen F., Johannesen I.L., Terkelsen A.J., Juhl G.I., Kristensen A.D., Sindrup S.H., Bach F.W., Jensen T.S. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology 2005, 102:1023-1030.
24. Galeotti N., Quattrone A., Vivoli E., Bartolini A., Ghelardini C. Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study. Neuroscience 2008, 153:814-822.
25. Haeseler G., Foadi N., Ahrens J., Dengler R., Hecker H., Leuwer M. Tramadol, fentanyl, and sufentanil but not morphine block voltage-operated sodium channels. Pain 2006, 126:234-244.
26. Hains B.C., Klein J.P., Saab C.Y., Craner M.J., Black J.A., Waxman S.G. Upregulation of sodium channel Nav13 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 2003, 23:8881-8892.
27. Jarvis M.F., Honore P., Shieh C.C., Chapman M., Joshi S., Zhang X.F., Kort M., Carroll W., Marron B., Atkinson R., Thomas J., Liu D., Krambis M., Liu Y., McGaraughty S., Chu K., Roeloffs R., Zhong C., Mikusa J.P., Hernandez G., Gauvin D., Wade C., Zhu C., Pai M., Scanio M., Shi L., Drizin I., Gregg R., Matulenko M., Hakeen A., Gross M., Johnson M., Marsh K., Wagoner K., Sullivan J.P., Faltynek C.R., Krafte D. A-803467, a potent and selective Nav18 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A 2007, 104:8520-8525.
28. Kennedy J.D. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem 2007, 50:2547-2556.
29. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990, 37:57-84.
30. Lersch C., Schmelz R., Eckel F., Erdmann J., Mayr M., Schulte-Frohlinde E. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advance colorectal cancer. Clin Colorectal Cancer 2002, 2:54-58.
31. Lindstrom P., Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987, 28:45-50.
32. London C., Hoyt S.B., Parsons W.H., Williams B.S., Warren V.A., Tschirret-Guth R., Smith M.M., Priest B.T., McGowan E., Martin W.J., Lyons K.A., Karaman B.V., Jochnowitz N., Garcia M.L., Felix J.P., Dean B., Abbadie C., Kaczorowski G.J., Duffy J.L. Imidazolpyridines: a novel class of hNav17 channel blockers. Bioorg Med Chem Lett 2008, 18:1696-1701.
33. Maingret F., Coste B., Padilla F., Clerc N., Crest M., Korogod S.M., Delmas P. Inflammatory mediators increase Nav19 current and excitability in nociceptors through a coincident detection mechanism. J Gen Physiol 2008, 131:211-225.
34. Mao J., Chen L.L. Systemic lidocaine for neuropathic pain relief. Pain 2000, 87:7-17.
35. Muraglia M., Franchini C., Corbo F., Scilimati A., Sinicropi M.S., De Luca A., De Bellis M., Conte Camerino D., Tortorella V. Synthesis of beta-proline like derivatives and their evaluation as sodium channel blockers. J Heterocycl Chem 2007, 44:1099-1103.
36. Peters T. All about albumin, biochemistry, genetics, and medical applications 1996, Academic Press, New York, NY.
37. Priest B.T., Kaczorowski G.J. Blocking sodium channels to treat neuropathic pain. Expert Opin Ther Targets 2007, 11:291-306.
38. Priest B.T., Murphy B.A., Lindia J.A., Diaz C., Abbadie C., Ritter A.M., Liberator P., Iyer L.M., Kash S.F., Kohler M.G., Kaczorowski G.J., MacIntyre D.E., Martin W.J. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav19 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci U S A 2005, 102:9382-9387.
39. Rawson N.S., Harding S.R., Malcolm E., Lueck L. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 1998, 51:1343-1355.
40. Wainer I.W., Kaliszan R., Noctor T.A. Biochromatography using immobilized biopolymers: a new approach to the determination of pharmacological properties. J Pharm Pharmacol 1993, 45:367-373.
41. Webster R.G., Brain K.L., Wilson R.H., Grem J.L., Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005, 146:1027-1039.
42. Williams B.S., Felix J.P., Priest B.T., Brochu R.M., Dai K., Hoyt S.B., London C., Tang Y.S., Duffy J.L., Parsons W.H., Kaczorowski G.J., Garcia M. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav17. Biochemistry 2007, 46:14693-14703.
43. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-1774.
44. Wu S.N., Chen B.S., Wu Y.H., Peng H., Chen L.T. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology 2009, 30:677-685.
45. Xiao W., Naso L., Bennett G.J. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med 2008, 9:505-517.